Relationship between serum 25-hydroxyvitamin D3 level and prognosis in acute myeloid leukemia patients treated with demethylation therapy
Objective To investigate the relationship between serum 25-hydroxyvitamin D3[25-(OH)D3]level and the prognosis in acute myeloid leukemia(AML)patients treated with demethylation therapy.Methods A total of 118 AML patients received azacitidine and/or venclexta combined chemotherapy for 10-28 days.Serum 25-(OH)D3 level was detected before treatment,which showed that 77 patients had low serum 25-(OH)D3 level(low group)and 41 patients had normal serum 25-(OH)D3 level(normal group).The general data of the two groups were collected.The patients were followed up for 0.5-54 months.The survival curve was drawn and the prognosis of the two groups was analyzed.Results There were no significant differences in gender ratio,proportion of more than 65 years old,WBC,bone marrow original cell ratio and peripheral blood original cell ratio before treatment between low group and normal group(P＞0.05).There was no statistical difference in the complete remission rate between low group and normal group(76.6％vs.78.0％)(P＞0.05).The 2-year recurrence-free survival rates of low group and normal group were 36.8％and 15.1％,and the 2-year survival rates were 47.2％and 53.6％,respectively,which were no statistical differences between the two groups(P＞0.05).Conclusion The serum 25-(OH)D3 level is not associated with the prognosis of AML patients treated with demethylation therapy.
NETL
NSTL
万方数据
